Login
Evidence Feed
About
Diagnostics
New
Top genes
FAQ
Contact us
^
Login
Contact us
to learn more about
our Premium Content: News alerts, weekly reports and conference planners
BIOMARKER:
FGFR2 mutation
i
Other names:
FGFR2, BEK, CD332, CEK3, CFD1, ECT1, JWS, K-SAM, KGFR, TK14, TK25, Fibroblast growth factor receptor 2
Contact us
to learn more about our Premium Content:
News alerts, weekly reports and conference planners
Entrez ID:
2263
Related biomarkers:
Expression
Mutation
CNA
Fusion
Others
‹
FGFR2 N549K (7)
FGFR2 rearrangement (7)
FGFR2 P253R (3)
FGFR2 K310R (2)
FGFR2 translocation (2)
ARID1A K1238fs + FGFR2 R210Q (1)
BAP1 mutation + FGFR2 rearrangement (1)
FDFT1 rearrangement + FGFR2 rearrangement (1)
FGFR2 A391E (1)
FGFR2 B252W (1)
FGFR2 C382R (1)
FGFR2 E250G (1)
FGFR2 E565A (1)
FGFR2 E565G (1)
FGFR2 E565K (1)
FGFR2 F276C (1)
FGFR2 M540_I541insMM (1)
FGFR2 N549D (1)
FGFR2 N549H (1)
FGFR2 N549T (1)
FGFR2 N550K (1)
FGFR2 S252W (1)
FGFR2 V564F (1)
FGFR2 V564I (1)
FGFR2 V564L (1)
FGFR2 Y375C (1)
FGFR2 Y376C (1)
PIK3CA mutation + FGFR2 rearrangement (1)
PIK3CB mutation + FGFR2 rearrangement (1)
PIK3R1 mutation + FGFR2 rearrangement (1)
TP53 mutation + FGFR2 rearrangement (1)
FGFR2 C383R (0)
FGFR2 K660N (0)
FGFR2 W290C (0)
FGFR2 wild-type (0)
FGFR2 N549K (7)
FGFR2 rearrangement (7)
FGFR2 P253R (3)
FGFR2 K310R (2)
FGFR2 translocation (2)
ARID1A K1238fs + FGFR2 R210Q (1)
BAP1 mutation + FGFR2 rearrangement (1)
FDFT1 rearrangement + FGFR2 rearrangement (1)
FGFR2 A391E (1)
FGFR2 B252W (1)
FGFR2 C382R (1)
FGFR2 E250G (1)
FGFR2 E565A (1)
FGFR2 E565G (1)
FGFR2 E565K (1)
FGFR2 F276C (1)
FGFR2 M540_I541insMM (1)
FGFR2 N549D (1)
FGFR2 N549H (1)
FGFR2 N549T (1)
FGFR2 N550K (1)
FGFR2 S252W (1)
FGFR2 V564F (1)
FGFR2 V564I (1)
FGFR2 V564L (1)
FGFR2 Y375C (1)
FGFR2 Y376C (1)
PIK3CA mutation + FGFR2 rearrangement (1)
PIK3CB mutation + FGFR2 rearrangement (1)
PIK3R1 mutation + FGFR2 rearrangement (1)
TP53 mutation + FGFR2 rearrangement (1)
FGFR2 C383R (0)
FGFR2 K660N (0)
FGFR2 W290C (0)
FGFR2 wild-type (0)
›
Associations
(30)
News
Trials
Search handles
@ArndtVogel
@JiaJennyLiu
@VivekSubbiah
@anandoncologist
@marklewismd
@sonpavde
Search handles
@ArndtVogel
@JiaJennyLiu
@VivekSubbiah
@anandoncologist
@marklewismd
@sonpavde
Filter by
Latest
10ms
FGFR inhibition in #urothelialcarcinoma #bladdercancer at #ASCO23 - 1)The THOR Phase III trial in advanced #urothelialcarcinoma (UC) with FGFR2/3 mutations/fusions: Erdafitinib extended overall survival (OS) v taxane or vinflunine chemotherapy (median 12.1 v 7.8 mo, HR 0.64,… https://t.co/AM7hNC5Db6 (@sonpavde)
10 months ago
Clinical • Metastases
|
FGFR2 (Fibroblast growth factor receptor 2)
|
FGFR2 mutation • FGFR2 fusion
|
Balversa (erdafitinib) • Javlor (vinflunine)
11ms
What may also be relevant to GI cancers is the simultaneous Cancer Discovery publication at @ASCO #ASCO23 of RLY-4008- the first highly selective FGFR2 inhibitor with activity across FGFR2 alterations and resistance mutations with the clinical science symposium @CD_AACR with… https://t.co/YUjSUPRVYK (@VivekSubbiah)
11 months ago
Clinical
|
FGFR2 (Fibroblast growth factor receptor 2)
|
FGFR2 mutation
|
lirafugratinib (RLY-4008)
over1year
🔥The Co‐mutational Spectrum Determines the Therapeutic Response in Murine FGFR2 Fusion‐Driven Cholangiocarcinoma @HEP_Journal https://t.co/TC5aUZdkWK 🔥Combination therapies for targeting FGFR2 fusions in cholangiocarcinoma @trendscancer https://t.co/JCPSnToFCc (@ArndtVogel)
over 1 year ago
Combination therapy
|
FGFR2 (Fibroblast growth factor receptor 2)
|
FGFR2 mutation • FGFR2 fusion
over1year
Fascinating case of cholangiocarcinoma with dual IDH1 and FGFR2 mutations - 2/3 trials mentioned @VivekSubbiah open at our site @kinghorncancer - sequencing and choice now can be tricky when patient may be eligible for multiple trials. @WIN_Consortium (@JiaJennyLiu)
over 1 year ago
Clinical
|
FGFR2 (Fibroblast growth factor receptor 2) • IDH1 (Isocitrate dehydrogenase (NADP(+)) 1)
|
FGFR2 mutation
over1year
Exceptional Response to Erdafitinib in #FGFR2-Mutated Metastatic Pancreatic Ductal Adenocarcinoma: https://t.co/pFXGwH2DFc #PancSM #PancreaticCancer #MolecularInsights @jgong15 @DrArsenOsipov @DrHendifar (@JNCCN)
over 1 year ago
FGFR2 (Fibroblast growth factor receptor 2)
|
FGFR2 mutation
|
Balversa (erdafitinib)
over1year
Exceptional Response to Erdafitinib in FGFR2-Mutated Metastatic #PancreaticCancer #OpenAccess in @JNCCN from @DrHendifar & colleagues @CedarsSinai https://t.co/pBdy0yqRC9 For young onset, KRAS wild type pancreatic cancers, don’t forget to look for alternative driver fusions. (@Aiims1742)
over 1 year ago
KRAS (KRAS proto-oncogene GTPase) • FGFR2 (Fibroblast growth factor receptor 2)
|
FGFR2 mutation • KRAS wild-type • RAS wild-type
|
Balversa (erdafitinib)
over2years
Erdafitinib for Advanced #urothelialcarcinoma and tumor FGFR2/3 mutations/fusions- updated results-101 treated-ORR 40%, median PFS 5.5 months (mo), DOR 6 mo (31% 1-year DOR), time to response 1.4 mo, OS 11.3 mo @y_loriot @AndreaNecchi-https://t.co/6ocRJgnLp0 @practiceupdate (@sonpavde)
over 2 years ago
FGFR2 (Fibroblast growth factor receptor 2)
|
FGFR2 mutation • FGFR2 fusion
|
Balversa (erdafitinib)
over2years
Somatic FGFR2/3 mutations & advanced #urothelialcarcinoma-if both EV,Erdafitinib options, following may support erdafitinib before EV: 1) prospective trial data in specific population, 2) drug hitting specific target likely best used early (caveat-truism for all drugs,need data) (@sonpavde)
over 2 years ago
Clinical
|
FGFR2 (Fibroblast growth factor receptor 2)
|
FGFR2 mutation
|
Balversa (erdafitinib)
almost3years
Infigratinib Opens Up Options for Patients With FGFR2-Mutant Cholangiocarcinoma @MJavle @MDAndersonNews #cancer https://t.co/qoGwdK9jmc (@OncLive)
almost 3 years ago
Clinical
|
FGFR2 (Fibroblast growth factor receptor 2)
|
FGFR2 mutation
|
Truseltiq (infigratinib)
3years
Excellent oral presentations at #CCFAC2021 today. Our collaboration with @javlemilind on resistance mutations in FGFR2+ cholangiocarcinoma was presented. I also enjoyed the talk by @pashtoonkasi on the clinical utility of liquid biopsy in cholangiocarcinoma. #hpbcsm (@MasonIsraelPhD)
3 years ago
Clinical • Liquid biopsy
|
FGFR2 (Fibroblast growth factor receptor 2)
|
FGFR2 mutation
almost4years
If you're not testing your cholangiocarcinoma patients for driver mutations, e.g. FGFR2, you are now undertreating your patients #ASCO20 (@marklewismd)
almost 4 years ago
Clinical
|
FGFR2 (Fibroblast growth factor receptor 2)
|
FGFR2 mutation
4years
The trial required documentation of mutation in FGFR3 or fusion of FGFR2/3. Luminal 1 subtype which is less responsive to checkpoint inhibitors and has more frequent FGFR mutations might respond better to Erdafitinib. #bladdercancer #immunotherapy @BladderCancerMD (@anandoncologist)
4 years ago
Checkpoint inhibition
|
FGFR2 (Fibroblast growth factor receptor 2) • FGFR3 (Fibroblast growth factor receptor 3)
|
FGFR2 mutation • FGFR3 mutation
|
Balversa (erdafitinib)
Share
^
^
Full access to predictive biomarker details and heatmap analytics are available with a VERI Account.
Sign up for FREE
Already have an account?
Login
Full access to predictive biomarker details and heatmap analytics are available with a VERI Account.
Sign up for FREE
Already have an account?
Login